Oslo, 16 February 2023: On the basis of Navamedic ASA's (the "Company") annual
general meeting's resolution on 2 June 2022 to authorise the board of directors
of the Company (the "Board") to issue new options to the executive management
and other leaders in the group under the Company's long-term incentive program,
the Board has resolved to issue 1.400.000 new options to the Company's executive
management. Each option will upon exercise give the option holder the right to
acquire one share in the Company. The options are granted without consideration.

Pursuant to the vesting schedule and certain other terms and conditions of the
grant, 1/3 of the share options will vest on the first anniversary of the day of
grant, 1/3 of the share options will vest on the second anniversary of the day
of grant, and the remaining 1/3 of the share options will vest on the third
anniversary of the day of grant.

The exercise price of each option is NOK 33.0. Options that are not exercised
within 12 months after the third anniversary of the date of grant, will subject
to certain limitations, lapse without any compensation to the holder.

The following primary insiders of the Company have received options on the terms
described above:

* Kathrine Gamborg Andreassen, CEO in the Company, has been granted 200,000
options. Following the grant Kathrine Gamborg Andreassen, with her related
parties own 666,668 shares and 305,000 options in the Company.

* Lars Hjarrand, CFO in the Company, has been granted 200,000 options. Following
the grant Lars Hjarrand, with his related parties own 260,882 shares and 275,000
options in the Company.

* Ole Henrik Eriksen, CBDO in the Company, has been granted 200,000 options.
Following the grant Ole Henrik Eriksen, with his related parties own 500,000
shares and 275,000 options in the Company.

* Astrid T. Bratvedt, CSO in the Company, has been granted 200,000 options.
Following the grant Astrid T. Bratvedt, with her related parties own 527,000
shares and 275,000 options in the Company.

* Tony Brejke, COO in the Company, has been granted 200,000 options. Following
the grant Tony Brejke, with his related parties own 807,117 shares and 200,000
options in the Company.

* Alexander Lidmejer, Commercial Director Rx in the Company, has been granted
200,000 options. Following the grant Alexander Lidmejer, with his related
parties own 2,400 shares and 275,000 options in the Company.

* Karianne Femtehjell Olsen, Sales and Marketing Director CH in the Company, has
been granted 200,000 options. Following the grant Karianne Femtehjell Olsen,
with her related parties own 0 shares and 230,000 options in the Company.

Please see attached notifications of trade for further details.

For further information please contact:

Lars Hjarrand, CFO. E-mail: lars.hjarrand@navamedic.com

Phone +47 917 62842

This information is subject of the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5 -12 of the Norwegian
Securities Trading Act.